EUVIMEDEUVIMED entdecken
Crossref

Designing a Novel Coamorphous Salt Formulation of Telmisartan with Amlodipine to Enhance Permeability and Oral Absorption

Yuta Hatanaka, Hiromasa Uchiyama, Shun Kaneko, Keisuke Ueda iD, Kenjirou Higashi iD, Kunikazu Moribe iD, Shingo Furukawa, Mai Takase, Shinya Yamanaka, Kazunori Kadota iD, Yuichi Tozuka iD

Molecular Pharmaceutics · 07.08.2023 · 20 (8) · 4071-4085

DOI: 10.1021/acs.molpharmaceut.3c00226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 27.07.2023. Verfasst von Yuta Hatanaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Formulation Design and Pharmaceutical Technology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Jap…. Hauptthemen laut MEDLINE: Amlodipine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Hosokawa Powder Technology Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coamorphous formulation is a useful approach for enhancing the solubility of poorly water-soluble drugs via intermolecular interactions. In this study, a hydrogen-bonding-based coamorphous system was developed to improve drug solubility, but it barely changed the apparent permeability (Papp) of the drug. This study aimed to design a novel coamorphous salt using ionic interactions to improve drug permeability and absorption. Telmisartan (TMS), with an acidic group, was used to form a coamorphous salt with basic amlodipine (AML). Evaluation of the physicochemical properties confirmed the formation of a coamorphous salt via ionic interactions between the amine group of AML and the carboxyl group of TMS at a molar ratio of 1:1. The coamorphous salt of TMS/AML enhanced the partitioning of both drugs into octanol, indicating increased lipophilicity owing to the interaction between TMS and AML. The coamorphous salt dramatically enhanced TMS solubility (99.8 times that of untreated TMS) and decreased AML solubility owing to the interaction between TMS and AML. Although the coamorphous salt showed a decreased Papp in the permeation study in the presence of a thicker unstirred water layer (UWL) without stirring, Papp increased in the presence of a thinner UWL with stirring. The oral absorption of TMS from the coamorphous salt increased by up to 4.1 times compared to that of untreated TMS, whereas that of AML remained unchanged. Although the coamorphous salt with increased lipophilicity has a disadvantage in terms of diffusion through the UWL, the UWL is thin in human/animal bodies owing to the peristaltic action of the digestive tract. Dissociation of the coamorphous salt on the membrane surface could contribute to the partitioning of the neutral form of drugs to the membrane cells compared with untreated drugs. As a result, coamorphous salt formation has the advantage of improving the membrane permeation and oral absorption of TMS, owing to the enhanced solubility and supply of membrane-permeable free TMS on the surface of the membrane.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineLeukemia, Myeloid, AcuteAnimalsHumansTelmisartanSolubilityPermeabilityWater

Stichwörter der Autor:innen

amlodipinecoamorphous saltionic interactionoral absorptionpermeabilitytelmisartan

Substanzen

TelmisartanAmlodipineWater

Autor:innen und Institutionen

  • Department of Formulation Design and Pharmaceutical Technology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan.
  • Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan.
  • Division of Applied Sciences, Muroran Institute of Technology, Muroran 050-8585, Japan.

ORCID-Profile: Keisuke Ueda, Kenjirou Higashi, Kunikazu Moribe, Kazunori Kadota, Yuichi Tozuka

Förderung

  • Hosokawa Powder Technology Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Hatanaka, Y., Uchiyama, H., Kaneko, S., Ueda, K., Higashi, K., Moribe, K., Furukawa, S., Takase, M., Yamanaka, S., Kadota, K., & Tozuka, Y. (2023). Designing a Novel Coamorphous Salt Formulation of Telmisartan with Amlodipine to Enhance Permeability and Oral Absorption. Molecular Pharmaceutics, 20(8), 4071-4085. https://doi.org/10.1021/acs.molpharmaceut.3c00226

Vancouver

Hatanaka Y, Uchiyama H, Kaneko S, Ueda K, Higashi K, Moribe K, et al. Designing a Novel Coamorphous Salt Formulation of Telmisartan with Amlodipine to Enhance Permeability and Oral Absorption. Molecular Pharmaceutics. 2023;20(8):4071-4085. doi:10.1021/acs.molpharmaceut.3c00226

BibTeX
@article{Hatanaka2023,
  author = {Hatanaka, Yuta and Uchiyama, Hiromasa and Kaneko, Shun and Ueda, Keisuke and Higashi, Kenjirou and Moribe, Kunikazu and Furukawa, Shingo and Takase, Mai and Yamanaka, Shinya and Kadota, Kazunori and Tozuka, Yuichi},
  title = {Designing a Novel Coamorphous Salt Formulation of Telmisartan with Amlodipine to Enhance Permeability and Oral Absorption},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {8},
  pages = {4071--4085},
  doi = {10.1021/acs.molpharmaceut.3c00226}
}
Kostenlos starten →